PHARMACOLOGICAL CORRECTION OF ADMA-ENOS-ASSOCIATED TARGETS IN PREECLAMPSIA
Methylated L-arginine analogues, such as asymmetric dimetylarginine (ADMA) and monomethylarginine (L-NMMA), are endogenous inhibitors of endothelial nitric oxide (e-NOS). It has been recently established that the maternal plasma concentrations of ADMA are higher in women with preeclampsia and the elevated ADMA concentrations are a predictor of preeclampsia. The previously presented studies showed that L-arginine on an ADMA-like model of L-NAME-induced endothelial dysfunction was effective in increasing the activity of endothelial NO synthase and the generation of nitric oxide. The eNOS activator resveratrol, antioxidants, potentiated polyclonal antibodies against eNOS, etc. were effective on this model. Investigations of endothelium-protective activity have been under way on other ADMA-eNOS-associated experimental models of metabolic syndrome X, homocysteine-, hypoestrogenism-, and sepsis-induced endothelial dysfunction and endothelial dysfunction in reactive postvaccination vasculitis.